Lidds AB represents strong values and a clear corporate philosophy. The company is committed to excellence and innovation in the field of pharmaceuticals. Lidds AB focuses on developing innovative drug delivery solutions to meet unmet medical needs. With a vision to improve patient outcomes, the company places a strong emphasis on quality, research, and development. Lidds AB also believes in establishing strategic partnerships to enhance its global presence and foster collaborative growth. By consistently aligning its actions with its core values, Lidds AB aims to make a positive impact on patients' lives and contribute to the advancement of the healthcare industry.

Lidds AB is primarily present in Sweden.

Lidds AB, a renowned pharmaceutical company, has successfully accomplished several significant milestones. The company has achieved regulatory approval for its innovative pharmaceutical products, indicating its commitment to quality and efficacy. Lidds AB has also secured strategic partnerships and collaborations with leading industry players, fostering growth and expanding its market reach. Furthermore, the company has demonstrated outstanding research and development capabilities, resulting in the successful development of groundbreaking treatments and therapies. Lidds AB's dedication to advancing medical science and improving patient outcomes has earned it a prominent position in the market, making it a highly reputable and reliable player in the pharmaceutical industry.

Lidds AB is a Swedish pharmaceutical company dedicated to developing innovative treatments in the field of anti-infective medicine. Founded in 2014, Lidds focuses on the development of localized drug delivery systems targeting infectious diseases and cancers. The company's technology platform, known as NanoZolid®, offers long-lasting drug release and increased therapeutic efficacy. Lidds AB has a strong research and development pipeline, with its lead product, Liproca® Depot, currently in late-stage clinical trials for the treatment of localized prostate cancer. With a commitment to advancing healthcare and improving patient outcomes, Lidds AB continues to make significant contributions to the pharmaceutical industry.

The main competitors of Lidds AB in the market are Company X, Company Y, and Company Z. These companies compete with Lidds AB in the same industry, offering similar products and services. Lidds AB strives to differentiate itself from its competitors by providing unique solutions, strong customer relationships, and consistent innovation. Despite facing competition, Lidds AB has established itself as a prominent player in the market by focusing on its strengths and delivering value to its customers.

Lidds AB is primarily active in the pharmaceutical industry.

The business model of Lidds AB revolves around the development and commercialization of innovative pharmaceutical products within the field of drug delivery. Lidds AB focuses on creating solutions that enhance the effectiveness and safety of existing drugs, allowing for improved treatment outcomes and patient experiences. By leveraging their expertise in bioadhesive drug delivery technologies, Lidds AB aims to provide novel solutions for various medical conditions. Through continuous research and development efforts, Lidds AB strives to address unmet medical needs and deliver value to patients, healthcare providers, and stakeholders in the pharmaceutical industry.

Lidds KGV ir -0,22.

Lidds KUV ir 0.

AlleAktien kvalitātes vērtējums Lidds ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Lidds.

gaidāmā Lidds peļņa ir -35,14 milj. SEK.

Lidds AB is a Swedish pharmaceutical company that focuses on developing innovative drugs for the treatment of serious diseases. The company's business model relies on research and development to identify and develop novel drugs that have the potential to achieve significant therapeutic advancements. The company operates in multiple sectors, including oncology, autoimmune diseases, and inflammatory diseases. In the oncology sector, the focus is on developing treatment options for pancreatic cancer and leukemia. In the autoimmune diseases sector, the company concentrates on drugs for the treatment of diseases like rheumatoid arthritis and multiple sclerosis. In the inflammatory diseases sector, the focus is on developing drugs for the treatment of diseases such as Crohn's disease and ulcerative colitis. One of Lidds AB's main products is Liproca Depot, a drug for the treatment of prostate cancer. Liproca Depot is an innovative long-acting drug that is approved in the USA and Europe. The company is also developing LTX-315, an immunotherapeutic medication for the treatment of cancer. Another product being developed by Lidds AB is LIH223, a drug designed for the treatment of leukemia in adults. LIH223 is an orally administered preparation that inhibits the growth of leukemia cells. Lidds AB's strength lies in its ability to integrate new technologies and innovative approaches in drug research and development. The company collaborates closely with leading research groups and institutions to develop new concepts and technologies that contribute to improving the effectiveness and tolerability of drugs. Lidds AB's business model is based on partnerships and collaborations with other companies in the pharmaceutical industry. The company seeks partnerships to market its drugs in different regions of the world. It has also formed partnerships with other companies to utilize new technologies and methods for drug development. Overall, Lidds AB's business model is focused on the development of drugs that have the potential to achieve significant therapeutic advancements and improve the lives of patients. The company relies on innovation, research, and international collaborations to achieve its goals.

Lidds izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Lidds vai uzņēmums nedod dividendes.

Lidds ISIN ir SE0001958612.

Lidds WKN ir A12DLG.

Lidds simbols ir LIDDS.ST.

Pēdējo 12 mēnešu laikā Lidds maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Lidds plāno maksāt dividendes 0 SEK apmērā.

Lidds pašreizējā dividendu rentabilitāte ir .

Lidds maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Lidds pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 SEK. Tas atbilst dividendes ražībai 0 %.

Lidds tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Lidds apmērā 0 SEK, kas tika izmaksāta 16.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.09.2024..

Pēdējās dividendes izmaksa notika 16.09.2024..

Gadā 2023, Lidds izmaksāja 0 SEK dividendes.

Lidds dividendes tiek izmaksātas SEK.